.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

McKesson
AstraZeneca
QuintilesIMS
Moodys
Cantor Fitzgerald
Julphar
US Department of Justice
Dow
Deloitte
Argus Health

Generated: September 23, 2017

DrugPatentWatch Database Preview

Claims for Patent: ► Subscribe

« Back to Dashboard

Claims for Patent: ► Subscribe

Title: Triiodoisophthalamide X-ray contrast agent
Abstract:Novel X-ray contrast agents, i.e., N,N'-bis(2,3-dihydroxypropyl)-5-N-(2-hydroxyethyl)glycolamido-2,4,6-triiod oisophthalamide.
Inventor(s): Lin; Youlin (Chesterfield, MO)
Assignee: Mallinckrodt, Inc. (St. Louis, MO)
Application Number:06/338,382
Patent Claims: 1. N,N'-Bis(2,3- dihydroxypropyl)-5-N-(2-hydroxyethyl)glycolamido-2,4,6-triiodoisophthalamid e.

2. A radiological composition containing N,N'-bis(2,3-dihydroxypropyl)-5-N-(2-hydroxyethyl)glycolamido-2,4,6-triiod oisophthalamide in a sufficient amount to provide satisfactory X-ray visualization together with a pharmaceutically acceptable radiological vehicle.

3. In a method for X-ray visualization wherein a radiological composition containing an X-ray contrast agent in a pharmaceutically acceptable radiological vehicle is injected in a sufficient amount to provide adequate visualization and thereafter X-ray visualization carried out, the improvement comprising or utilizing as the radiological composition a composition containing N,N'-bis(2,3-dihydroxypropyl)-5-N-(2-hydroxyethyl)glycolamido-2,4,6-triiod oisophthalamide in a sufficient amount to provide satisfactory X-ray visualization together with a pharmaceutically acceptable radiological vehicle.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Fuji
Daiichi Sankyo
Citi
Cipla
Fish and Richardson
Novartis
Johnson and Johnson
Moodys
Harvard Business School
Deloitte

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot